| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor | Frank Vinluan | 08/12/20 | New York |
| FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs | Frank Vinluan | 01/22/20 | Boston |
| Wave Stock Crashes After Decision to Halt Duchenne Drug Studies | Melissa Fassbender | 12/16/19 | Boston |
| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| In an About-Face, FDA Approves Second Sarepta Muscular Dystrophy Drug | Sarah de Crescenzo | 12/13/19 | Boston |
| Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More | Frank Vinluan | 08/23/19 | National |
| FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns | Ben Fidler | 08/19/19 | Boston |
| Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More | Alex Lash | 12/21/18 | National |
| Bio Roundup: DIY Biohacking, PCSK9 Data, Solid Setback & More | Frank Vinluan | 03/16/18 | National |
